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venous administration of amiodarone, but may be fatal if
not recognized early and treated in a timely manner.
Herein we report two cases of acute liver failure after
intravenous administration of amiodarone. One patient
with cerebral infarction was admitted to our emergency
department. He received intravenous amiodarone for the
acute heart failure with paroxysmal atrial fibrillation
(PAF). The patient developed acute liver failure (ALF)
and died of multiple organ failure (MOF). The other pa-
tient was admitted to our emergency department due to
PAF. Intravenous amiodarone was administrated and the
PAF was converted to a normal sinus rhythm 6 hours
later. The patient developed ALF and acute renal failure
(ARF). He was successfully treated with blood purifica-
tion in combination with other conservative therapy.
Neither patient had a history of alcohol abuse or hepa-
titis virus infection. Furthermore, abdominal ultrasound
examinations showed no significant findings in either
patient.
Most published reports on acute hepatitis following
amiodarone administration show a similar pattern of
symptoms and laboratory results, including elevated
alanine aminotransferase, aspartate aminotransferase,
and total bilirubin, but severe renal impairment is rare. In
general, liver injury is rapidly reversible after* Corresponding author. Emergency Department, Beijing TianTan
Hospital, Capital Medical University, Beijing 100050, China.
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As shown in Table 1, we have found five case reports of
fatal hepatotoxicity caused by intravenous amiodarone,
published between 1984 and 2010.1e4 Intravenous amio-
darone was used in all five cases to treat supraventricular
tachyarrhythmia, which is not regarded as the best indi-
cation of amiodarone. ARF was the major cause of death
in patients with intravenous amiodarone-induced ALF.
Although there are no randomized trials to confirm its
efficacy, early continuous renal replacement therapy has
become a major part of the management of patients with
ARF and ALF.
The mechanism for intravenous amiodarone-induced
hepatotoxicity is not fully understood. Polysorbate 80, an
excipient used to maintain the stability of amiodarone in
solution, is believed to be responsible for the hepatotox-
icity. However, a recent caseecontrol study argues that
hepatotoxicity induced by intravenous amiodarone cannot
be clearly differentiated from ischemic hepatitis, claiming
that they are in fact the same entity.5 Future studies should
focus on the underlying mechanisms for intravenous
amiodarone-induced ALF and ARF.
In summary, hepatotoxicity is a rare, but potentially
fatal, adverse effect of intravenous amiodarone. Amio-
darone indication should be followed precisely and he-
patic and renal parameters should be carefully monitored
during and after its administration. Early continuous
hemofiltration may improve the prognosis of severe cases
of acute renal and liver failures after amiodarone
administration.& Formosan Medical Association. All rights reserved.
Table 1 Summary of five published cases of fatal hepatotoxicity after intravenous amiodarone administration.
Age/sex Amiodarone
dose until
hepatotoxic
signs (mg)
Indication Laboratory parameters and symptoms
of liver toxicity
Cause of death Day of death
from ALF
Histology Ref
28, M 1500 Persistent Af AST 20,040 U/L, ALT 20,360 U/L, bilirubin
116 mmol/L, hyperammonemia, PT [,
hepatomegaly, anuria, requiring dialysis,
encephalopathy
Hepatic coma
and acute renal
failure
14 n/d 1
60, M 1500 Persistent Af ALT 570 U/L, AST 1200 U/L, bilirubin
95 mmol/L, Cr 274 mmol/L, PT [,
hepatomegaly, oliguria,
hyperammonemia, renal failure,
encephalopathy
Hepatic coma
and acute
renal failure
4 Confluent liver
cell necrosis
1
75, F 600 Supra-ventricular
tachycardia
ALT 60e70-fold[, bilirubin 408 mmol/L,
jaundice, PT [, encephalopathy,
Encephalopathy 31 n/d 2
64, M 1200 Af ALT 9,308 U/L Bilirubin 64 mmo/L
Cr 332 mmo/L. jaundice, PT [,
metabolic acidosis, acute renal failure
Metabolic acidosis
acute renal
failure
3 Extensive necrosis
for drug or ischemia
3
59, M 1200 Af AST 7,388 IU/L, ALT 5,352 IU/L, PT [,
Cr 328 mmol/L requiring dialysis
Acute renal failure 3 Acute hepatic
necrosis
4
AfZ atrial fibrillation; ALTZ alanine aminotransferase; AST Z aspartate aminotransferase; Cr Z creatinine; F Z female; M Z male; n/d Z not determined; PT Z prothrombin time.
D
ru
g-in
d
u
ce
d
a
cu
te
live
r
fa
ilu
re
295
296 J.-G. Li et al.References
1. Kalantzis N, Gabriel P, Mouzas J, Tiniakos D, Tsigas D,
Tiniakos G. Acute amiodarone-induced hepatitis. Hepatogas-
troenterology 1991;38:71e4.
2. Giannattasio F, Salvio A, Varriale M, Picciotto FP, Di
Costanzo GG, Visconti M. Three cases of severe acute hepatitis
after parenteral administration of amiodarone: the active
ingredient is not the only agent responsible for hepatotoxicity.
Ann Ital Med Int 2002;17:180e4.3. MacFadyen RJ, Palmer TJ, Hisamuddin K. Rapidly fatal acute
amiodarone hepatitis occurring in the context of multiple
organ failure. Int J Cardiol 2003;91:245e7.
4. Murphy BP, Coldeway J, Raeside DA. Fatal acute fulminant
hepatic failure caused by parenteral amiodarone: a case
report. SMJ 2009;54:58.
5. Gluck N, Fried M, Porat R. Acute amiodarone liver toxicity likely
due to ischemic hepatitis. Isr Med Assoc J 2011;13:748e52.
